Even though the incidence of complications in transcatheter aortic valve replacement (TAVR) have significantly decreased, there is one in particular that remains a concern since, when mild, it is associated to increased events rate. This complication is prosthetic paravalvular leak , which happens between the native annulus and the stent. The Lotus valve, completely repositionable, uses a...
Bicuspid aortic valve (BAV) disease affects 1%-2% of the population and manifests with severe aortic stenosis in the middle-aged. It characterizes for a very different anatomy with more calcification than the tricuspid aortic valve. At present, surgical aortic valve replacement (SAVR) is the first treatment indication. TAVR in this scenario has shown, in different studies,...
Aortic valve replacement (AVR) is indicated for symptomatic aortic stenosis (AS), while close follow-up is recommended for asymptomatic patients, unless they have elevated aortic gradients, low ejection fraction, or abnormal stress tests. However, the optimal timing to perform AVR is uncertain, especially with recent evidence suggesting that patients with AS associated with signs of myocardial...
The Treatment of severe aortic stenosis has experienced a significant revolution with TAVR, especially in high and intermediate risk patients, and it is now extending to low risk patients. In the US, nearly half of patients under 64 are being treated with TAVR. One of the fundamental questions that still remains unanswered revolves around device...
Both Acurate Neo2 and its predecessor, Acurate Neo, have proven their safety and efficacy in the percutaneous treatment of severe aortic stenosis. The Acurate platform offers a lower gradient and a larger effective orifice area, as well as a low risk of periprocedural complications, according to previous registries. However, the first-generation Acurate device had some...
Treating tricuspid regurgitation (TR) has gained increasing importance in interventionism. There is abundant literature on the negative natural evolution of this condition and its unfavorable prognosis, as well as the clinical challenges associated to optimal medical treatment. Among its percutaneous treatment options, both edge-to-edge repair devices (TEER), as showed in TriValve and TRILUMINATE trials, and...
During SOLACI-SBHCI 2023, our traditional education program for young interventionists ProEducar Fellows Course was held. Discover the presentations of the prestigious interventionists that made part of this 13th edition here below. Dr. Gustavo Vignolo (UY) – “Trigger: STEMI learning clinical case” PRESENTATION Dr. Roger Renault Godinho (BRA) – “Why and how should I use Radial access? Step by Step” PRESENTATION...
Dr. Thourani has presented the ALIGN AR, a single arm, multicenter and non-blinded trial on the use of JenaValve in symptomatic patients with severe aortic regurgitation and high surgical risk. Safety primary end point was a composite variables including all-cause mortality at 30 days, stroke, major bleeding, vascular complications, kidney failure, need for definite pacemaker...
Aortic valve replacement (AVR) is recommended for symptomatic aortic stenosis (AS), while close monitoring is the advised strategy for asymptomatic patients, unless they have elevated aortic gradients, reduced ejection fraction, or abnormal stress tests. However, the optimal timing for AVR remains uncertain, especially in light of recent evidence suggesting that AS patients showing signs of...
The second group of Women Interventionists sponsored by SOLACI has started the training on structural disease as part of our scholarship program at the Instituto Cardiovascular de Rosario (ICR). The program will take place over the course of this week in different centers across Argentina. During the session, the grant holders were able to attend...